Spots Global Cancer Trial Database for fludara
Every month we try and update this database with for fludara cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Randomized Double Cord Blood Transplant Study | NCT00067002 | Leukemia, Lymph... Leukemia, Myelo... Leukemia, Myelo... Lymphoma, Non-H... | Expanded alloge... One Unmanipulat... Rituxan Melphalan Thiotepa Fludarabine Cyclophosphamid... Mesna Total body irra... | 1 Month - 80 Years | M.D. Anderson Cancer Center | |
| Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT00941928 | Leukemia Pediatric Cance... | Epratuzumab Fludarabine Cyclophosphamid... Mesna Infusion of NK ... Interleukin-2 | - | M.D. Anderson Cancer Center | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 | NCT04167696 | Acute Myeloid L... Myelodysplastic... | CYAD-02 ENDOXAN Fludara | 18 Years - | Celyad Oncology SA | |
| Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies | NCT00048737 | Lymphoma Leukemia | Zevalin Radioim... Rituximab Fludarabine Cyclophosphamid... Allogeneic Stem... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support | NCT00506857 | Hematologic Mal... | Busulfan Fludarabine | - 75 Years | M.D. Anderson Cancer Center | |
| FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | NCT00254410 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Mitoxantrone Rituximab Filgrastim | - 70 Years | M.D. Anderson Cancer Center | |
| Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma | NCT00698009 | Neuroblastoma | Fludarabine Cyclophosphamid... Natural Killer ... Mesna Interleukin-2 | - | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) | NCT01096992 | Leukemia | Bendamustine Fludarabine Rituximab | 16 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma | NCT00506129 | Lymphoma Disorder Relate... | Fludarabine Melphalan Allogeneic Tran... Thymoglobulin | - 70 Years | M.D. Anderson Cancer Center | |
| Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention | NCT02423915 | Leukemia Lymphoma | Rituximab Fludarabine Cyclophosphamid... Total Body Radi... Fucosylated Reg... Cord Blood Infu... Mycophenolate m... Sirolimus Bone Marrow Asp... G-CSF Non-Fucosylated... | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Adoptive Cell Therapy Across Cancer Diagnoses | NCT03296137 | Cancer | Autologous tumo... Ipilimumab Nivolumab proleukin Cyclophosphamid... Fludara | 18 Years - 70 Years | Herlev Hospital | |
| Busulfan and Fludarabine in Patients With AML and MDS | NCT00502905 | Leukemia | Busulfan Fludarabine | - 66 Years | M.D. Anderson Cancer Center | |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | NCT01572662 | Leukemia Acute Myeloid L... Acute Lymphocyt... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Non-Hodgkins Ly... Hodgkins Lympho... Multiple Myelom... Myelodysplastic... | Fludarabine mon... Busulfan Stem Cell Infus... Tacrolimus Methotrexate G-CSF | 5 Years - 75 Years | M.D. Anderson Cancer Center | |
| Busulfan and Fludarabine in Patients With AML and MDS | NCT00502905 | Leukemia | Busulfan Fludarabine | - 66 Years | M.D. Anderson Cancer Center | |
| Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) | NCT01096992 | Leukemia | Bendamustine Fludarabine Rituximab | 16 Years - | M.D. Anderson Cancer Center | |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 | NCT04167696 | Acute Myeloid L... Myelodysplastic... | CYAD-02 ENDOXAN Fludara | 18 Years - | Celyad Oncology SA | |
| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | NCT00473551 | Leukemia Lymphoma Myeloma | Rituximab Cyclophosphamid... Fludarabine Mesna Radiation Treat... Stem Cell Trans... Sirolimus Anti-third Part... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma | NCT00290511 | Lymphoma | Fludarabine Mitoxantrone Rituximab Zevalin Dexamethasone | 60 Years - | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00525876 | Lymphoma | Cyclophosphamid... Fludarabine Rituximab Alemtuzumab Allogeneic Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies | NCT00521859 | Hematologic Mal... | Cloretazine Fludarabine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | NCT00038831 | Acute Myelogeno... Myelodysplastic... Chronic Lymphoc... | Mylotarg Fludarabine Melphalan Anti-thymocyte ... Stem cell trans... | 12 Years - 75 Years | M.D. Anderson Cancer Center | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) | NCT02932956 | Liver Cancer | GAP T cells Cytoxan Fludara | 1 Year - 21 Years | Baylor College of Medicine | |
| Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells | NCT01362452 | Leukemia Lymphoma | T-Cell Infusion Cord Blood Infu... | 1 Year - 75 Years | M.D. Anderson Cancer Center | |
| Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma | NCT00338377 | Melanoma | Dendritic Cell ... Cyclophosphamid... Fludarabine T-Cells Interleukin-2 Mesna Intrathecal T-C... Intrathecal Int... | 12 Years - | M.D. Anderson Cancer Center | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies | NCT00521859 | Hematologic Mal... | Cloretazine Fludarabine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
